Please login to the form below

Not currently logged in

People, April, 2008

Recent high-profiles moves in the pharmaceutical and healthcare industries

MOVER OF THE MONTH: Stephanie Kelly

Stephanie Kelly has joined Actelion UK as brand manager for hypertension drug Tracleer. Stephanie joined from Bausch & Lomb (UK) where she was a product manager for the Vision Care division. She began her career in the pharma industry with Merck, Sharp and Dohme in New Zealand. Her initial role was as a marketing analyst before becoming associate product manager for Merckís cardiology drugs Cozaar and Hyzaar. Stephanie moved to the UK in 2006 and joined Bausch & Lomb (UK) to gain consumer experience in a more condensed and retail-orientated marketplace.


  • Lisa Bright has joined Gilead Sciences as general manager, UK and Ireland. Lisa will report to Paul Carter, senior vice-president, commercial operations, international, and will be based in the companyís Cambridge office. Prior to Gilead, Lisa was vicepresident and general manager for GlaxoSmithKline (GSK) New Zealand. She has held a number of additional roles at GSK, including vice-president of sales for GSK UK.

  • Di Smith has been appointed area manager of the Solvay Business Support Centre with responsibility for HR administration. The move follows the launch of a new European Human Resources transformation project, which sees payroll and benefits provision brought under one umbrella. In her new role she will support Solvay Healthcare in the UK and in Ireland, Solvay Interox, Solvay Speciality Chemicals and Solvay Polymers.

  • Robert Hull has joined ScopeMedical as medical director. Robert completed his PhD in pharmacology at Kingís College London. He has a wealth of research and pharma industry experience spanning a number of therapy areas including cardiology, oncology, gastrointestinal disorders and bone diseases. Robertís achievements include co-establishing the James Black Foundation (JBF) ñ a biomedical research organisation ñ with Sir James Black in 1987 and he has most recently held the post of head of pharmacology at JBF. Dean Williams has joined ScopeMedical as business development manager. Dean has considerable pharma industry experience and has worked as both a medical and hospital rep for Bristol-Myers Squibb and Pharmacia. Relocating to the UK from South Africa in 2001, Dean subsequently joined UCB Pharma as an executive product specialist. Sue Adams has joined as account director. She gained a BSc (Hons) in nutrition from Kings College London, UK, before joining the pharma industry. Working for Schering Healthcare and, most recently, Bayer Schering Pharma, Sue has 12 yearsí experience including the key roles of marketing manager and communications manager working on a range of therapy areas.



  • Fiona Walton has joined Edelman Health as a senior account manager. Fiona worked previously at Ruder Finn (both in the UK and New York), Fleishman-Hillard and Novartis (Basel), where she worked as interim product manager. At Edelman, she will work across major global accounts for Pfizer and Novo Nordisk, as well as providing departmental support. Svea Luebcke has transferred permanently to London from Edelmanís Frankfurt office, where she worked for more than two years. As account manager, she will be a key part of the Bayer Healthcare team and provide support on Pfizer business. Jessie Prynne has been appointed assistant account executive following successful completion of the Edelman gradute rotation scheme.

  • Louise Fish has been appointed associate director of corporate communications and public affairs consultancy, Hanover. Louise was previously communications director of NICE for seven years. She will start her new position at the end of April 2008 and will work with directors Andrew Harrison and James Gurling.


  • Dr Joan Barnard, an established ABPI Code of Practice expert, has launched a new consultancy venture. The consultancy offers a range of services, including consulting, copy approval and medical sign-off, training and compliance, and will support companies as they work within the ABPI Code and prepare for its revisions, expected in July 2008. Dr Sharon McCullough has joined as medical director, and Ian Hale has joined as director of operations and compliance. Sharon and Ian will continue their existing business commitments alongside Code in Practice.


  • Dr Anita Sexton has been appointed vice-president of international operations at Synexus with responsibility for the management and operation of Synexus research centres in the UK, Eastern Europe, India and South Africa. Anita has over 12 yearsí experience in pharmaceutical contract research and R&D. She joins from Quest Diagnostics Clinical Trials (formerly SmithKline and Beecham), where she was director of business strategy.


  • Henryk Bohdanowicz has joined Euro RSCG Life as commercial director to lead the medical communications team. He also has responsibility for e-learning and closed loop marketing/e-detailing. Henryk joins from a similar position at Lowe Healthcare Europe.

  • Tai Friedmann has joined Adventis Health division Affiniti as account director, from Huntsworth Health. Tai has worked in the pharma industry for over 10 years having started her career as a sales rep for Rhone Poulenc Rorer, Upjohn and Innovex. Linda Dunn joins Adventis Health division Affiniti as senior copywriter,from Huntsworth Health. Linda has a broad range of experience across OTC, primary and secondary care accounts, and she was recognised at recent PM Society, Rx Club of New York and Best of Health awards for her memorable Rectogesic barbed wire toilet roll GP press ad. Gaurav Sanganee joins Adventis Health division Roundhouse HealthAd as anaccount executive.

  • Spectrum Regulatory Solutions has hired Judy Knight and Ann Stanley. Judy has been appointed project manager, bringing to the role 20 yearsí experience in regulatory affairs. Ann will be responsible for quality control, and has a background in a legal environment.




  • Healthcare agency Woolley Pau has appointed Alex Mellor as an account director. Alex has 10 yearsí experience in the pharma industry, seven of which have been in healthcare advertising. Alex has worked previously with Grey and Torre Lazur McCann and will be working on a number of key accounts. Lara Kelly joins Woolley Pau as office manager. She previously worked with Criminal, a clothing company.

  • Healthcare communications agency, Aurora, has hired Si‚n Hurst as associate director. Si‚n joins from Huntsworth Health where she worked in a number of therapeutic areas including respiratory, oncology, gastroenterology and menís health. She has more than 11 yearsí experience in healthcare communications and joins Aurora with responsibility for the overall management and strategic direction of key client accounts. Si‚n joins the senior management team, reportingto joint MD Claire Eldridge, and will work on existing UCB business, as well as new business activities.



  • Bell Pottinger Group has formed Bell Pottinger Health, a new business dedicated to leading the expansion of its health franchise. Bell Pottinger Health, will be led by De Facto Communications CEO Richard Anderson in the role of chairman and by Shipra Singh, as managing director. The new agency, which will work in conjunction with De Facto, is establishing an international footprint, reflecting the global needs of clients in the pharma sector. Shipra was previously managing director of healthcare and wellbeing at Hill & Knowlton, where she has worked since 2001. Shipra has expertise in both international and UK communications programmes. She has worked in healthcare PR for 12 years. Mike Wort becomes the managing director of De Factoís life science business while Anna Dunphy joins as account director. Following 20 yearsí working in the pharma industry with Glaxo, SmithKline and Wellcome in various senior roles in the UK and overseas, Mike has helped emerging firms communicate with financial audiences in the UK and Europe. In his last industry role, Mike, was investor relations manager at Wellcome, following which he co-founded Europeís first specialist investor relations consultancy.

  • Joy Allardice has been made account executive at Succinct Healthcare Communications working on accounts with a number of clients including Bayer Schering, sanofi-aventis and GSK. Joy has over 6 yearsí experience in pharma latterly as a key account executive with Leo Pharma.

  • Online specialist pharm job site,, has appointed Ryan Murrant to join the expanding business development team. Ryan has a strong account management background both as a recruitment consultant and most recently from selling recruitment advertising solutions at Wiley- Blackwell. James Buckley has been promoted to team leader, business development. James will manage the dayto- day running of the business development team and reports to Greg Holt.

  • MSA Market Media has appointed Nicky Hutchens to the role of account manager. Nicky joins MSA from Gem and brings with her a wealth of knowledge in both OTC and Rx markets.


    Tell us about your latest appointments: email Please ensure that photographs are 300dpi in resolution and labelled with names.
  • Share

    Subscribe to our email news alerts


    Add my company

    KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

    Latest intelligence

    Actinic keratosis – a common skin condition that can lead to skin cancer
    PMGroup talks to Volker Koscielny, Chief Medical Officer at Almirall, about the importance of remaining vigilant about skin checks, the prevalence of actinic keratosis in the UK and the steps...
    Man vs microbe: the fight against antimicrobial resistance
    How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics...
    Is trust the key factor in digital HCP engagement? New whitepaper from Graphite Digital
    Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising...